APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate whether presence of the APOE epsilon4 allele is related to the pathologic progression of preclinical Alzheimer disease (AD), as reflected by change in Mini-Mental State Examination (MMSE) scores among persons in the preclinical phase of AD, and cognitively intact adults confirmed as dementia-free during the 6-year assessment period. METHOD: In a population-based sample, participants were stratified according to APOE genotype (epsilon4 or non-epsilon4) and whether they received a diagnosis of AD at the end of either a 3- or 6-year assessment period. Participants were aged 75 years and older, and were nondemented at baseline. At the end of the 3-year period, 17.2% of non-epsilon4 and 26.7% of epsilon4 carriers became demented. For the 6-year period those percentages were 11.2% for non-epsilon4 carriers and 16.9% for epsilon4-carriers. RESULTS: Individuals in the preclinical phase of AD showed greater decline on the MMSE as compared to nondemented adults. However, the decline was most marked in the 3 years prior to clinical diagnosis. Further, APOE-epsilon4 genotype did not modify the rate of decline among to-be-demented participants, as well as individuals who would remain free of AD. CONCLUSIONS: Although possession of the APOE epsilon4 allele is a risk factor for AD in old age, it does not modify the progression of the disease during the preclinical period. Further, in the absence of preclinical dementia, APOE did not influence global cognitive change in nondemented persons.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
. Cerebral blood flow in dementia.
Hachinski, V. C., Iliff, L. D., Zilhka, E., Du Boulay, G. H., McAllister, V. L., Marshall, J., Russell, R. W. R., & Symon, L. (1975) · Archives of Neurology · doi:10.1001/archneur.1975.00490510088009 · Cited by 3,186
The Preclinical Phase of Alzheimer Disease: A 22-Year Prospective Study of the Framingham Cohort
Elias, M. F., Beiser, A., Wolf, P. A., Au, R., White, R. F., & D'Agostino, R. B. (2000) · Archives of Neurology · doi:10.1001/archneur.57.6.808 · Cited by 716
Fratiglioni, L., Grut, M., Forsell, Y., Viitanen, M., Grafström, M., Holmen, K., Ericsson, K., Bäckman, L., Ahlbom, A., & Winblad, B. (1991) · Neurology · doi:10.1212/wnl.41.12.1886 · Cited by 525
Self-citationHaan, M. N. (1999) · JAMA · doi:10.1001/jama.282.1.40 · Cited by 457
Estrogen use, APOE, and cognitive decline: Evidence of gene–environment interaction
Yaffe, K., Haan, M., Byers, A., Tangen, C., & Kuller, L. (2000) · Neurology · doi:10.1212/wnl.54.10.1949 · Cited by 371
Small, B. J., Fratiglioni, L., Viitanen, M., Winblad, B., & Bäckman, L. (2000) · Archives of Neurology · doi:10.1001/archneur.57.6.839 · Cited by 329
Self-citationBondi, M. W., Salmon, D. P., Galasko, D., Thomas, R. G., & Thal, L. J. (1999) · Psychology and Aging · doi:10.1037//0882-7974.14.2.295 · Cited by 235
LANGE, K. L., BONDI, M. W., SALMON, D. P., GALASKO, D., DELIS, D. C., THOMAS, R. G., & THAL, L. J. (2002) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617702870096 · Cited by 129
Farrer, L. A. (1997) · JAMA · doi:10.1001/jama.1997.03550160069041 · Cited by 124
Cited by
Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy
Liu, C.-C., Kanekiyo, T., Xu, H., & Bu, G. (2013) · Nature Reviews Neurology · doi:10.1038/nrneurol.2012.263 · Cited by 3,459
Sex modifies the APOE ‐related risk of developing Alzheimer disease
Altmann, A., Tian, L., Henderson, V. W., Greicius, M. D., & Alzheimer's Disease Neuroimaging Initiative Investigators (2014) · Annals of Neurology · doi:10.1002/ana.24135 · Cited by 891
“68 16 [ 12 –16 ] 16 [ 12 –18 ] 16 [ 12 –18 ] 16 [ 12 –18 ] 16 [ 12 –18 ] 16 [ 14 –18 ] 0 .”
Neuropsychological and neuroimaging changes in preclinical Alzheimer's disease
TWAMLEY, E. W., ROPACKI, S. A. L., & BONDI, M. W. (2006) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617706060863 · Cited by 273
Impaired olfaction is associated with cognitive decline and neurodegeneration in the brain
Dintica, C. S., Marseglia, A., Rizzuto, D., Wang, R., Seubert, J., Arfanakis, K., Bennett, D. A., & Xu, W. (2019) · Neurology · doi:10.1212/wnl.0000000000006919 · Cited by 237
Age-related decline in brain resources magnifies genetic effects on cognitive functioning
Lindenberger, U. (2008) · frontiers in Neuroscience · doi:10.3389/neuro.01.039.2008 · Cited by 231
“…of decline in AD after the clinical diagnosis has been made (e.g., Corder et al., 1995; Growdon et al., 1996), and even progression from the preclinical stage to clinically verified AD is indistinguishable for carriers and non-carriers of the e4 allele (Bäckman et al., 2003; Bunce et al., 2004a).”
BackgroundResult
Metadata
- Authors
- Bunce, D., Fratiglioni, L., Small, B. J., Winblad, B., & Bäckman, L.
- Venue
- Neurology
- Published
- 2004-09-14
- Volume
- 63
- Issue
- 5
- Pages
- 816-821
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2042240757
- Cited by
- 110
- References
- 9
- FWCI
- 3.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging. https://app.cochat.ai/papers/10.1212/01.wnl.0000137041.86153.42
- The paper
- Bunce, D., Fratiglioni, L., Small, B. J., Winblad, B., & Bäckman, L. (2004). APOE and cognitive decline in preclinical Alzheimer disease and non-demented aging. Neurology. https://doi.org/10.1212/01.wnl.0000137041.86153.42
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.